June 2016, Vol. 5, No. 5

← Back to Issue

Personalized Medicine in Oncology: Expanding Our Knowledge of Precision Medicine

Personalized Medicine in Oncology: Expanding Our Knowledge of Precision Medicine

Letter to Our Readers

Benson-pic-98pxDear Colleague,

This issue of Personalized Medicine in Oncology (PMO) is a testament to how far we’ve come in our understanding of, and novel approaches to, the treatment of cancer. Armed with knowledge of molecular biomarkers, genetic mutations, genomics, immunotherapeutics, and targeted therapies, we are better able to treat patients with cancer to obtain longer survival and higher quality of life than ever before.

This month, Christos Fountzilas, MD, and Virginia G. Kaklamani, MD, DSc, provide a review of BRAF mutations and implications when considering treatment strategies for patients with this mutation.

In our Interview with the Innovators department, we talk with Chief Scientific Officer Paul W. Dempsey, PhD, and Chief Medical Officer Paul Y. Song, MD, of Cynvenio about their multiple-template strategy that analyzes DNA from circulating tumor cells, circulating cell-free DNA in blood, and tissue biopsies, as well as the initiation of their clinical trial in triple-negative breast cancer. We hope you find our exchange insightful and helpful.

Is there a topic you would like to see discussed in PMO? An innovator in the oncology community you’d like to have interviewed? Please contact us with your comments and request at editorial@personalizedmedonc.com.

As always, thank you for your loyal readership. It is our pleasure to serve you in your quest to provide personalized medicine to your patients.


Coeditor in Chief
Personalized Medicine in Oncology

AACR - June 16, 2016

Pembrolizumab Elicits Response in Patients with Merkel Cell Carcinoma

Immunotherapy with the programmed death 1 (PD-1) inhibitor pembrolizumab induced durable responses in a phase 2 clinical trial of a virus-related cancer. Among 26 patients with Merkel cell carcinoma (MCC) treated in the trial, 12 of 14 patients (86%) who responded to pembrolizumab have ongoing responses after a median follow-up [ Read More ]

AACR - June 16, 2016

Nivolumab Represents New Standard in Recurrent Head and Neck Cancer

Programmed death 1 (PD-1) inhibitor treatment with nivolumab significantly improves survival in patients with squamous cell cancer of the head and neck that progresses after platinum-based therapy, according to data from the phase 3 CheckMate-141 trial. Based on these data, “nivolumab therefore represents a new standard of care option for [ Read More ]